KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Shares Outstanding (Weighted Average) (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $46.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 72.62% to $46.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.9 million through Dec 2025, up 72.62% year-over-year, with the annual reading at $46.9 million for FY2025, 72.62% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $46.9 million in Q4 2025 for Inovio Pharmaceuticals, down from $52.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $234.6 million in Q3 2022 to a low of $17.4 million in Q4 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $85.2 million across 5 years, with a median of $32.9 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 90.46% in 2023 and later skyrocketed 98.99% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $17.4 million in 2021, then rose by 14.27% to $19.9 million in 2022, then increased by 11.51% to $22.2 million in 2023, then grew by 22.49% to $27.2 million in 2024, then surged by 72.62% to $46.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for INO at $46.9 million in Q4 2025, $52.2 million in Q3 2025, and $38.8 million in Q2 2025.